Jeffrey S Albert

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Neomed Institute, Epigenetix, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey S Albert. Retrieved from https://idiyas.com/inventor/jeffrey-s-albert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

Years Active: 2019-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12790314 - Substituted benzimidazoles, their preparation and their use as pharmaceuticals (2026-11-10),

2. 11981657 - Substituted benzimidazoles, their preparation and their use as pharmaceuticals (2024-05-14),

3. 11365186 - Substituted benzimidazoles, their preparation and their use as pharmaceuticals (2022-06-21),

4. 10836742 - N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals (2020-11-17),

5. 10703740 - Substituted benzimidazoles, their preparation and their use as pharmaceuticals (2020-07-07),

6. 10501459 - Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors (2019-12-10),

7. 10501438 - Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals (2019-12-10),

Title: The Innovative Mind of Jeffrey S. Albert

Introduction

Jeffrey S. Albert, a prominent inventor based in Montreal, Canada, has made significant contributions to the field of pharmaceuticals through his innovative research and development. With a remarkable portfolio of six patents, Albert has been dedicated to advancing medical science and providing potential solutions for various health-related challenges.

Latest Patents

One of Albert's latest patents focuses on substituted benzimidazoles, which pertain to their preparation and use as pharmaceuticals. This application highlights the importance of substituted benzimidazoles and their compositions in the treatment of diseases and conditions where bromodomain inhibition is crucial. Notably, these compounds have potential applications in treating proliferative disorders, autoimmune disorders, inflammatory conditions, dermal disorders, and various neoplasms, including tumors and cancers.

Career Highlights

Throughout his career, Albert has collaborated with esteemed organizations such as the Neomed Institute and Epigenetix, Inc. His work in these institutions has been instrumental in the development of innovative medical solutions and has positioned him as a key figure in pharmaceutical research.

Collaborations

In addition to his impressive career, Jeffrey S. Albert has worked alongside notable colleagues, including Malken Bayrakdarian and Andrew Griffin. These collaborations have allowed for the exchange of ideas and fostered an environment of innovative thinking, further enhancing the impact of their work in the field of pharmaceuticals.

Conclusion

In summary, Jeffrey S. Albert exemplifies the spirit of innovation with his extensive contributions to pharmaceutical science. His patents on substituted benzimidazoles reflect his commitment to addressing complex medical issues. Through collaboration and a passion for research, Albert continues to make strides in the field, impacting the future of medical treatments.

Profile summary based on public USPTO records.